On February 21, 2018, Dr. Harvey Berger, MD was appointed to the Board of Trustees at the Dana-Farber Cancer Institute. He is among six other newly appointed individuals who will serve on the Hospital’s governing body.
In addition to providing his leadership and expertise to the Dana-Farber team, Dr. Harvey Berger is the Executive Chairman of Medinol, Inc., a global interventional cardiovascular-device company. Dr. Berger joined the Medinol team in February of 2017. Prior to joining Medinol, Inc., he founded a global biotechnology company, ARIAD Pharmaceuticals, Inc., where he served as the company’s Chairman and Chief Executive Officer.
“As a governing trustee, I look forward to working closely with the outstanding leadership and trustees of the DFCI. CEO, Laurie Glimcher, and Board chair, Josh Bekenstein, have set a clear vision for the Institute in a world of personalized cancer medicines. The DFCI is second-to-none among cancer institutes and brings clinical scholarship, outstanding basic and translational research, and a historic dedication to patients to its mission every day. Being selected to work with them is a special honor for me,” said Harvey Berger.
Dr. Berger adds an extensive portfolio of experience in cardiology, oncology and life sciences. He has held both academic and administrative positions at Yale University, Emory University and University of Pennsylvania. Dr. Berger has published over 150 original papers, editorials, and reviews in scientific and medical journal and serves as an Established Investigator of the American Heart Association.